Lupin Ltd
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
- Market Cap ₹ 74,442 Cr.
- Current Price ₹ 1,633
- High / Low ₹ 1,728 / 890
- Stock P/E 38.9
- Book Value ₹ 314
- Dividend Yield 0.24 %
- ROCE 15.9 %
- ROE 14.3 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 5.21 times its book value
- The company has delivered a poor sales growth of 6.41% over past five years.
- Company has a low return on equity of 1.97% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9,641 | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | |
7,356 | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,200 | |
Operating Profit | 2,284 | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,811 |
OPM % | 24% | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% |
13 | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 120 | |
Interest | 41 | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 |
Depreciation | 332 | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 |
Profit before tax | 1,925 | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 |
Tax % | 30% | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | -10% | 38% | 20% |
1,340 | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 430 | 1,936 | |
EPS in Rs | 29.36 | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 |
Dividend Payout % | 14% | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 6% |
3 Years: | 10% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 21% |
3 Years: | 18% |
TTM: | 367% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 17% |
3 Years: | 12% |
1 Year: | 83% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 2% |
3 Years: | 2% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 |
Reserves | 5,115 | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 |
1,164 | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | |
2,475 | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,785 | |
Total Liabilities | 8,843 | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,997 |
3,000 | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 9,055 | |
CWIP | 311 | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 596 |
Investments | 2 | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 |
5,530 | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,272 | |
Total Assets | 8,843 | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,997 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,251 | 2,004 | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | |
-522 | -851 | -1,034 | -6,769 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | |
-663 | -857 | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | |
Net Cash Flow | 66 | 296 | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 83 | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 |
Inventory Days | 200 | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 |
Days Payable | 159 | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 |
Cash Conversion Cycle | 125 | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 |
Working Capital Days | 92 | 94 | 67 | 147 | 112 | 137 | 154 | 92 | 151 | 135 | 127 | 119 |
ROCE % | 33% | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 10h
- Today I.E., July 1, 2024, Lupin Limited Completed The Transfer Of Its Trade Generics Business In India To Lupin Life Sciences Limited, Wholly Owned Subsidiary Of The Company, As A Going Concern, On A Slump Sale Basis. Thus, The Transaction Has Been Completed. 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 28 Jun
- Judgement Of The Court Of Justice Of The European Union. 28 Jun
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 24 Jun
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Sep 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Jun 2016TranscriptPPT
Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]